Illumina (NASDAQ:ILMN) Upgraded by Royal Bank Of Canada to “Moderate Buy” Rating

Illumina (NASDAQ:ILMN) was upgraded by investment analysts at Royal Bank Of Canada to a “moderate buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

ILMN has been the topic of a number of other reports. Piper Sandler reduced their target price on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Citigroup boosted their target price on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Barclays lifted their price target on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Weiss Ratings cut shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $137.75.

Illumina Stock Performance

Illumina stock opened at $142.54 on Thursday. The company’s 50-day moving average price is $128.58 and its 200-day moving average price is $129.52. Illumina has a twelve month low of $78.55 and a twelve month high of $155.53. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company has a market cap of $21.57 billion, a PE ratio of 25.92, a price-to-earnings-growth ratio of 2.37 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the firm posted $0.97 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities research analysts forecast that Illumina will post 5.2 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Keith A. Meister sold 225,067 shares of Illumina stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the completion of the transaction, the director directly owned 3,604,441 shares of the company’s stock, valued at approximately $524,626,387.55. The trade was a 5.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 332,530 shares of company stock valued at $48,303,655. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Large investors have recently added to or reduced their stakes in the stock. Elyxium Wealth LLC purchased a new stake in Illumina in the 4th quarter valued at about $25,000. Board of the Pension Protection Fund purchased a new stake in Illumina in the 4th quarter valued at about $26,000. Creative Capital Management Investments LLC boosted its position in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after buying an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in Illumina in the 4th quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in Illumina in the 4th quarter valued at about $26,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.